If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oh gosh...
Look it up on Urban Dictionary.
Nightmarewalking - No, I've been in here since last June and have no intention of going anywhere. My missus suggested a clungefest recently and I haven't had time to look up the meaning yet, but it seemed interesting...
Chamberlin up 15% today. Trevor's next P&D well underway.
Nightmarewalking - There's a massive clungefest over at BRH, see you there...
Most probably just musing over whether AS will be true to his forecast of early May.
nightmare,
Typically that is true, Big pharma wait until all is proved up prior to stepping in. But this is not a typical situation, with AVCT about to generate huge sums ($ billions is not unfeasible) thus any interested party has a decision to make fairly soon, or could cost them significantly more that they would wish.
Starbright,
Disagree with the following points;
1. The current register is dominated by PI’s, many of whom would try to hold out for fantasy prices (can you imagine this board??). Thus execution risk would be extremely high.
The exact opposite is true. Large PI base = easy takeover.
2. It’s an intellectual capital business. Without the active support and commitment of the scientists and others who make the business work, there is little value to an acquirer. The senior team would have to be 100% onboard before a takeover could proceed.
Also not true. Multiple 3rd party partnerships actively & independently assessing the Affimer IP and the Precision IP is at an advanced clinical stage.
We need strong II to prevent any T/O and secure fair value.
Starbright - I agree its all conjecture at the moment and even following application there are delays meaning it can take up to 19 weeks to be listed at the moment. However, I don't want a 'dual listing' rumour to become engrained as when/if it will almost certainly be a cross-listing.
No worries. I agree with the sentiment that UK investors shouldn't be concerned(!) about the possibility of a NASDAQ listing. If it were to become a reality, it is more than likely to be a positive for existing holders.
Posters in this thread debating the merits of cross- vs dual- listings are (as my former US colleagues would have said) "well over their skis" at this point...
They are fair points StarBright
Ok agreed, my response was very high level.
I'll reply to my own question. Unless there is a statement from AS to the contrary somewhere I would have thought a cross-listing is much more likely than a dual listing. A cross-listing would be the same company listed on both exchanges.
I don’t think that AVCT is at all vulnerable to an unwanted takeover approach. This because:
1. The current register is dominated by PI’s, many of whom would try to hold out for fantasy prices (can you imagine this board??). Thus execution risk would be extremely high.
2. It’s an intellectual capital business. Without the active support and commitment of the scientists and others who make the business work, there is little value to an acquirer. The senior team would have to be 100% onboard before a takeover could proceed.
The point made by Wiggly earlier on another thread re NASDAQ is worth repeating:
" It has been mentioned before that currently AVCT is extremely vulnerable to a T/O. We need large sticky investors to prevent a cheap T/O. The value opportunity over the next 2 years, based on LFT sales and successful AVA6000 is so huge that unless we secure ourselves from T/O now we will not be able secure full value over the next 2 years. "
Timster - the impact of any potential NASDAQ listing can’t be assessed at this point because there are so many ways in which such a listing might be achieved. It’s not right for you to make the flat assertion that “...it wouldn’t impact on your UK shares...”.
Timster quick Q as a total novice regarding Nasdaq ,it appears the US value biotech more highly so if Avacta are listed there at what price would the listing be set , would it be the same as the uk ie presently 250p / $3 and dilution as i assume the new listing shares will be in addition to the uk
Apologies but I hope that makes sense and i am not just being stupid in asking
Is definitely going to be a dual listing and not a cross-listing ?
Is it definitely going to be a dual listing rather than a cross-listing ?
Jarbumkin it wouldn't impact on your UK shares and you wouldn't be issued NASDAQ shares.
It'd be a dual listing which would obviously attract investors from America as it's listed on thier stock exchange.
Make the timing of RNS's interesting too
How would the Share price in the UK be influenced by the Nasdaq listing? Also as a UK shareholder, would we get issued shares from the Nasdaq listing?
Further cash could be raised via Nasdaq listing, at a much higher valuation than current MC. The US II would likely love to take a big stake in AVCT with confirmed Covid test revenues to drive expansion of the Therapeutics business.
Who's "we" you're clearly not invested or you'd know there is enough funds for a year, even without LFT sales.
Revenue from LFT removes any risk of future placing.
Source: Company presentation, on you tube.
Yes I missed the link off the post of Miles, mistake made !!!
It's taken all of 1.5 hours but Waynesmith finally crosses the line in first place.